Acadian Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30K Buy
6,667
+4,976
+294% +$22.5K ﹤0.01% 1880
2026
Q2
$8K Sell
1,691
-13,375
-89% -$53.2K ﹤0.01% 1951
2026
Q1
$50K Buy
+15,066
New +$51.1K ﹤0.01% 1855
2023
Q3
– Sell
-31,736
Closed -$113K – 1785
2023
Q2
$113K Buy
+31,736
New +$102K ﹤0.01% 1383

Other funds holding ORMP

Acadian Asset Management's ORMP Position: Q3 2026 in Review

Acadian Asset Management increased its Oramed Pharmaceuticals (ORMP) stake by 294% in Q3 2026, buying an estimated $22.5K and bringing the position to 6,667 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

Acadian Asset Management first reported a position in ORMP in Q2 2023 and has held it in 4 quarters since. The position peaked at $113K in Q2 2023. 93 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

  • Acadian Asset Management held 6,667 shares of Oramed Pharmaceuticals worth $30K as of Q3 2026.
  • Acadian Asset Management bought 4,976 Oramed Pharmaceuticals shares in Q3 2026, an estimated $22.5K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2026, its #1880 holding.
  • Acadian Asset Management first reported a position in Oramed Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
  • Acadian Asset Management's Oramed Pharmaceuticals position peaked at $113K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.